Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07220343

Digital Phenotyping for Psychosocial Screening in Adolescents and Young Adults With Cancer

The overall goal of the proposed study is to use digital phenotyping to identify and triage at-risk patients and accelerate access to critical mental health services.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cancer Adolescents Neoplasms

Age range

10 year–25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stanford University

Palo Alto, California, 94304, United States

Location status: Recruiting

Location contact

Olivia Borge

CONTACT

[email protected]

650-723-9392

Victoria Crosgrove, Ph.D.

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 10-25 years old
  • Recent cancer diagnosis (>2 and <18 months since diagnosis)
  • Willing to carry smartphone on their person for duration of study participation
  • Willing to wear smartwatch for duration of study participation

Exclusion criteria

  • Significant physical or mental disability that prevents completion of study activities
  • Lack of proficiency in English or Spanish

Treatment and study plan

Device

Device

Participants will wear a wrist-based wearable device for 10 days to passively track physiological data (heart rate, steps, sleep, etc.).

Ecological Momentary Assessment (EMA) via My Personal Health Dashboard (MyPHD) Smartphone App

Behavioral

Participants will respond to ecological momentary assessments (EMA) via smartphone to actively report on sleep, mood, stress, and eating habits across a 10-day period.

Primary outcomes

  1. Change in Depressive Symptoms (Beck Depression Inventory - BDI)

    Time frame: Baseline, Day 10, 2 months

    The Beck Depression Inventory-II (BDI-II; range 0-63) will be used to measure changes in depressive symptoms among adolescents and young adults over time. Higher scores indicate greater depressive symptom severity.

Secondary outcomes

  1. Participant Retention Rate (MyPHD App and Wearable Device)

    Time frame: Baseline to 2 months

    Percentage of participants who remain active in the study through the 2-month follow-up period using the MyPHD app and wearable device.

  2. Adherence to EMA Prompts

    Time frame: Baseline to 2 months

    Mean percentage of EMA prompts completed by participants using the MyPHD mobile app during the 2-month study period. Completion will be assessed via EMA system analytics.

  3. Wearable Device Return and Use Rate

    Time frame: Baseline to 2 months

    Percentage of participants who return and use the wearable device as instructed during the study period. Device use will be tracked through backend device usage logs.

  4. Change in Anxiety Symptoms (Beck Anxiety Inventory - BAI)

    Time frame: Baseline, Day 10, 2 months

    Measures changes in self-reported anxiety symptoms across the study period.

  5. Change in PTSD Symptoms (CROPS)

    Time frame: Baseline

    PTSD symptoms are measured using the Child Report of Post-traumatic Symptoms (CROPS) for child participants.

  6. Change in PTSD Symptoms (PCL-5)

    Time frame: Baseline

    PTSD symptoms are measured using the PTSD Checklist for DSM-5 (PCL-5) for general population participants.

  7. Change in Sleep Quality (Pittsburgh Sleep Quality Index - PSQI)

    Time frame: Baseline, Day 10

    Assesses subjective sleep quality and patterns.

Study contacts

Contact information is provided by the study sponsor or research team.

Olivia Borge

CONTACT

[email protected]

(650) 723-9392

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Official study title

Using Digital Phenotyping to Optimize Psychosocial Risk Screening and Personalized Care: a Pilot Study in Adolescents and Young Adults With Cancer

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 23, 2025
Registry last updated
Dec 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.